Curavit Clinical Research Acquires Lindus Health’s CRO Assets to Expand Clinical Trial Services in Europe

Acquisition Expands Curavit’s Clinical Research Operations Across North America and Europe

Curavit Clinical Research, a clinical research organization (CRO) and Remote Clinical Site, has announced the acquisition of the CRO assets of Lindus Health.

The transaction expands Curavit’s operations into Europe and gives life science companies access to clinical research services across both North America and Europe.

The deal comes as Lindus Health shifts its business focus toward developing its own therapeutic pipeline under Lindus Therapeutics.

For Curavit, the acquisition adds European clinical research capabilities, teams and infrastructure to its existing U.S. operations. The company plans to use the combined capabilities to support decentralized, hybrid and traditional clinical trials.

Curavit Builds a More Connected Global CRO Model

Clinical trials are becoming more complicated for pharmaceutical and biotechnology companies.

Sponsors are under pressure to complete studies faster, reach more diverse patient populations and manage different regulatory requirements across countries.

Curavit believes the acquisition can help address these challenges by bringing its U.S. clinical research operations together with Lindus Health’s European CRO assets.

Instead of working with different CRO providers in different regions, sponsors will be able to work with one operational partner across North America and Europe.

The combined organization will support sponsors in pharma, biotechnology, medical technology and digital health.

Focus on Faster Trial Execution

One of the main goals of the expanded platform is to help sponsors reduce the time needed to start and conduct clinical studies.

Curavit will combine full-service CRO capabilities with its Remote Clinical Site infrastructure.

This model is designed to support different types of clinical studies, depending on what the sponsor needs.

For some studies, traditional clinical sites may remain the best option. For others, decentralized or hybrid approaches can make it easier for patients to participate.

The combined organization will support all three models.

European Expansion Gives Sponsors More Options

Before the acquisition, Curavit had established its clinical research and Remote Clinical Site capabilities primarily in the United States.

The addition of Lindus Health’s CRO assets gives the company a stronger presence in Europe.

This is important for sponsors planning multi-country clinical studies because patient recruitment, site activation and regulatory requirements can vary significantly between regions.

Curavit says its expanded operations can help sponsors manage these challenges through a single partner.

The company will also support remote patient recruitment and trial designs based on the needs of individual studies.

Curavit and Lindus Bring Different Capabilities Together

The acquisition combines several areas of clinical research expertise.

Lindus Health brings its European clinical assets and team, while Curavit contributes its U.S. CRO operations, clinical research technology and Remote Clinical Site infrastructure.

Together, these capabilities are intended to support studies from planning and recruitment through clinical execution and data collection.

Joel Morse, CEO and co-founder of Curavit, said sponsors should not have to choose between smaller regional CROs and large traditional providers when running international studies.

According to Morse, the combined organization is designed to provide sponsors with a more flexible option for conducting prospective clinical trials across North America and Europe.

Decentralized and Hybrid Trials Remain a Key Focus

Curavit has built its business around newer approaches to clinical research.

Decentralized clinical trials allow some study activities to take place outside traditional research sites. Patients may be able to complete certain visits remotely, depending on the study design.

Hybrid trials combine traditional site-based visits with remote activities.

These approaches can make participation easier for some patients and may help sponsors improve recruitment and retention.

Curavit's Remote Clinical Site operations are designed to support these models alongside traditional clinical trial services.

Supporting Patient Recruitment and Retention

Finding and keeping the right patients is one of the major challenges in clinical research.

A study can be delayed when recruitment takes longer than expected. Patients may also leave a study when frequent site visits or other requirements become difficult to manage.

Curavit says its expanded capabilities are designed to address some of these issues through remote recruitment, participant engagement and flexible trial models.

The company expects these capabilities to help sponsors improve participant retention while reducing some of the operational burden associated with clinical trials.

Broader Services for Life Science Companies

The combined organization will work with sponsors across several areas of the life sciences industry.

These include pharmaceutical companies, biotechnology companies, medical device developers and digital health companies.

Curavit provides clinical research services for decentralized and hybrid clinical trials, prospective real-world evidence studies and longitudinal participant engagement programs.

The addition of Lindus Health’s European CRO assets expands the geographic reach of these services.

Investors See Opportunity in the Changing Clinical Research Market

The acquisition also comes as the clinical research industry continues to move toward more technology-enabled models.

Nate Lentz, managing partner at Osage Venture Partners and a Curavit board member, said clinical research is changing quickly and sponsors increasingly need flexible approaches to generating clinical evidence.

He pointed to Curavit’s combination of clinical expertise, technology-enabled trial models and patient recruitment capabilities as an advantage in the changing market.

According to Lentz, these capabilities could position Curavit for continued growth as sponsors look for faster and more flexible ways to conduct clinical studies.

What the Acquisition Means for Clinical Trial Sponsors

For sponsors planning clinical programs in both the United States and Europe, the acquisition creates a more unified service model.

Companies can use Curavit's expanded capabilities for decentralized, hybrid or traditional studies without having to rely on separate regional providers for every part of the program.

The company is also positioning the platform around faster site activation, remote patient recruitment and participant-centered study execution.

The broader goal is to help sponsors generate high-quality clinical data while managing the operational and regulatory challenges that come with international studies.

Curavit’s Expanded Clinical Research Platform

Following the acquisition, Curavit will operate with clinical research capabilities spanning North America and Europe.

The company will continue to combine its CRO services with Remote Clinical Site operations and technology-enabled research models.

This gives sponsors access to a single partner for clinical programs that may require traditional sites, remote participation or a combination of both.

Curavit says the expanded platform is available to sponsors planning upcoming clinical programs across therapeutics, diagnostics, medical devices and digital health.